Patient centred biochemistry of COPD patients, their renal comorbidities and outcomes

Popular posts from this blog

2023 May to 2024 May in glimpse

Image
May 4th 2023-25th Birthday. May 5th.Invited to AIIMS Rishikesh as a panelist for G20 Y20 summit for discussion on 'Digital Health and Future of Healthcare' May 6th to May ending-Exploring Himalayas and conquering mountains.(Pics to be uploaded). June to September ending-Worked on an independent and interdisciplinary project on 'Value Based Medicine and AI in Healthcare'.It got published in Springer Nature and presented in IIIT Delhi in International conference on 'Big Data and Artificial Intelligence',Dec 7th to 9th. Meanwhile,worked along with SATHI (sathi.org) for a BIS ICONS standards project along with a team from Switzerland. And some cherry on cake with this grateful recognition and award from CUBE(Collaboratively Understanding Biology Education)-an initiative by Homi Bhabha Centre for Science Education-Tata Institute of Fundamental Research. https://www3.hbcse.tifr.res.in/research-development/collaboratively-understanding-biology-education-cub...
Read more

Healthy Diet Template by Dr Dinesh Datta

Image
Start Date-April 11th 2025 Breakfast Carrot+beetroot+pumpkin+cucumber+anjeer+walnut+dates+chia seeds+flax seeds+sabja Sprouts+coconut+carrot+Mulaga leaves+almonds Curd rice left over in water overnight Ragi+ulava+Sajja+Buttermilk 250ml Lunch time- 130PM Cabbage Pakoda Korra Java Sambar with 3 types of pappu A piece of Jaggery Sambar rice 1 glass barley water with Sabja Grilled Tuna and some Mayonnaise
Read more

Appraising efficacy of Semaglutide in Metabolic Syndrome

[04/02, 8:59 am] Sumit CBBLE: I understand that you're extremely well regarded for metabolic syndrome and its implications. I had a question for you: Could semaglutide help manage or possibly treat metabolic syndrome? @⁨Dr Rakesh Biswas⁩ [04/02, 9:01 am] Sumit CBBLE: Open to discussion and inputs from everyone regarding implications of semaglutide. [04/02, 9:18 am] Dr.Dinesh Datta: No evidence to support its use in Metabolic syndrome. It's a weight lowering agent. Population: Patients aged 45 years or older with preexisting cardiovascular disease and a body-mass index (BMI) of 27 or greater, without diabetes. Intervention: Weekly subcutaneous semaglutide at a dose of 2.4 mg. Comparision: Placebo. Outcome- Reduction in the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke over a mean follow-up period of 39.8 months.  This multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial included 17,604 patie...
Read more